U.S. markets closed

Eloxx Pharmaceuticals, Inc. (ELOX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.2300+0.0300 (+1.36%)
At close: 4:00PM EDT

2.2300 0.00 (0.00%)
After hours: 4:00PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close2.2000
Bid2.2300 x 1100
Ask2.2400 x 800
Day's Range2.1975 - 2.4500
52 Week Range2.0800 - 6.7700
Avg. Volume104,698
Market Cap106.62M
Beta (5Y Monthly)2.44
PE Ratio (TTM)N/A
EPS (TTM)-0.8620
Earnings DateMar 11, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Eloxx Pharmaceuticals Adds Additional Treatment Arm to Ongoing Phase 2 Clinical Studies for Cystic Fibrosis

    Eloxx Pharmaceuticals Adds Additional Treatment Arm to Ongoing Phase 2 Clinical Studies for Cystic Fibrosis

    Fifth Treatment Arm to Evaluate Safety of ELX-02 in Combination with Kalydeco (ivacaftor) Reaffirmed Data Readout for First Four Treatment Arms On Track for Second Half of 2021 WALTHAM, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) today announced the addition of a new study arm in the ongoing global Phase 2 clinical program for ELX-02 for the treatment of cystic fibrosis (CF) in patients with at least one G542X allele. The Phase 2 clinical program now includes a fifth treatment arm to evaluate safety of ELX-02 in combination with Kalydeco (ivacaftor), an FDA-approved CFTR (CF transmembrane conductance regulator) potentiator for the treatment of cystic fibrosis in patients who have at least one mutation in their CF gene amenable to ivacaftor. The Phase 2 trials are designed to evaluate the safety of ELX-02 and assess its biological activity. “We are extremely pleased to include this additional treatment arm in the ongoing Phase 2 clinical trial to further explore the potential of ELX-02 to treat cystic fibrosis,” said Sumit Aggarwal, President and Chief Executive Officer. “Given ELX-02’s potential to treat CFTR nonsense mutations and the synergistic effects of ELX-02 and ivacaftor seen to date in pre-clinical models, we believe that combination treatment with a CFTR potentiator, such as ivacaftor, provides the opportunity to improve clinical efficacy in the treatment of CF. We remain on track to present data from the first four treatment arms of the study in the second half of this year.” ELX-02 is currently in Phase 2 clinical trials in CF patients affected by nonsense mutations in the CFTR gene. The trial currently has sites in the U.S., Europe, Israel, Australia and Canada. Several planned Safety Review Committee meetings have occurred and allowed dose escalation up to the top dose level, and data have shown no drug-related serious adverse events reported to date. Multiple patients have progressed through the four-dose escalation treatment range. The program is partially funded by the Cystic Fibrosis Foundation (CFF). The U.S. Food and Drug Administration has granted orphan drug designation for ELX-02 for the treatment of CF. About Eloxx Pharmaceuticals Eloxx Pharmaceuticals, Inc. is engaged in the science of ribosome modulation, leveraging both its innovative TURBO-ZM™ chemistry technology platform in an effort to develop novel Ribosome Modulating Agents (RMAs) and its library of Eukaryotic Ribosome Selective Glycosides (ERSGs). Eloxx’s lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in clinical development focusing on cystic fibrosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx also has preclinical programs focused on select rare diseases including inherited diseases, cancer caused by nonsense mutations, kidney diseases, including autosomal dominant polycystic kidney disease, as well as rare ocular genetic disorders. For more information, please visit www.eloxxpharma.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of present and historical facts contained in this press release, including without limitation, statements regarding the expected timing of trials and results from clinical studies of our product candidate, the expansion of our clinical trial sites and the potential of our product candidate to treat nonsense mutations are forward-looking statements. Forward-looking statements can be identified by the words “aim,” “may,” “will,” “would,” “should,” “expect,” “explore,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “seeks,” or “continue” or the negative of these terms similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on management's current plans, estimates, assumptions and projections based on information currently available to us. Forward-looking statements are subject to known and unknown risks,uncertainties and assumptions, and actual results or outcomes may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to: our ability to progress any product candidates in preclinical or clinical trials; the uncertainty of clinical trial results and the fact that positive results from preclinical studies are not always indicative of positive clinical results; the scope, rate and progress of our preclinical studies and clinical trials and other research and development activities; the competition for patient enrollment from drug candidates in development; the impact of the global COVID-19 pandemic on our clinical trials, operations, vendors, suppliers, and employees; our ability to obtain the capital necessary to fund our operations; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; our ability to obtain financial in the future through product licensing, public or private equity or debt financing or otherwise; general business conditions, regulatory environment, competition and market for our products; and business ability and judgment of personnel, and the availability of qualified personnel and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as any such factors may be updated from time to time in our other filings with the SEC, accessible on the SEC’s website at www.sec.gov and the “Financials & Filings” page of our website at https://investors.eloxxpharma.com/financial-information/sec-filings All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, we have no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contact InvestorsJohn Woolfordjohn.woolford@westwicke.com443.213.0506 MediaLaureen Cassidylaureen@outcomescg.com

  • Eloxx Pharmaceuticals (ELOX) Is in Oversold Territory: What's Next?

    Eloxx Pharmaceuticals (ELOX) Is in Oversold Territory: What's Next?

    Eloxx Pharmaceuticals (ELOX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

  • Eloxx Buys Zikani Therapeutics In An All-Stock Deal; Shares Gain

    Eloxx Buys Zikani Therapeutics In An All-Stock Deal; Shares Gain

    Shares of Eloxx Pharmaceuticals gained 1.2% to close at $3.36 on April 1 after the clinical-stage biopharmaceutical company announced the acquisition of Zikani Therapeutics. The all-stock transaction is likely to strengthen the company’s ribosomal RNA-targeted therapies for the treatment of rare diseases and oncology. Per the terms of the deal, Zikani’s shareholders were granted 7.6 million Eloxx (ELOX) common shares and 16% ownership of the combined entity. Zikani, an emerging leader in the science of ribosome modulation, is leveraging its innovative TURBO-ZM chemistry technology platform to develop novel Ribosome Modulating Agents (RMAs) as therapeutics for people with limited treatment options, the company said. ELX-02 is currently in Phase 2 clinical trials in Cystic Fibrosis (CF) patients, who are affected by nonsense mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Notably, nonsense mutations cause around 10%-12% of rare inherited diseases. Therefore, the company expects ELX-02 along with the TURBO-ZM library of compounds to significantly expand to include the treatment of many other rare diseases and certain cancers. Along with CF, the company intends to file an IND in 2022 for first-of-its-kind oral therapy for protein restoration in patients with nonsense mutations in Recessive Dystrophic Epidermolysis Bullosa (RDEB), and Junctional Epidermolysis Bullosa (JEB). Eloxx Chairman Tomer Kariv said, “With the strength of our ELX-02 program for cystic fibrosis, this acquisition provides us with the opportunity to amplify the potential of our innovative science by developing a new class of therapies to treat diseases with limited to no treatment options under the stewardship of leaders with a proven ability to translate technology into treatments for patients.” (See Eloxx stock analysis on TipRanks) Following the deal announcement, Piper Sandler analyst Edward Tenthoff reiterated a Buy rating and a price target of $6 (78.6% upside potential) on the stock. In a note to investors, Tenthoff said that the combined entity is likely to initially focus on developing oral RMAs in rare orphan skin disease, Recessive Dystrophic Epidermolysis Bullosa and Junctional Epidermolysis Bullosa, with an IND filing expected in 2022. The consensus rating among analysts is a Moderate Buy based on 1 Buy and 1 Hold. The average analyst price target stands at $4.50 and implies upside potential of 33.9% to current levels. Shares have gained 22.6% over the past six months. Eloxx scores a 9 out of 10 from TipRanks’ Smart Score rating system, indicating that the stock has strong potential to outperform market expectations. Related News: McCormick’s 1Q Results Beat Expectations As Sales Outperform CarMax’s Quarterly Profit Beats Analysts’ Expectations; Shares Tank 7% Franklin Covey Posts Smaller-Than-Feared 2Q Loss But Sales Disappoint; Shares Tank After-Hours More recent articles from Smarter Analyst: General Motors’ 1Q Vehicle Sales Rise On Strong Auto Demand Ford’s U.S. Sales Rise 1% In 1Q On EV Strength Gates Industrial Lifts 1Q Revenue Outlook; Street Sees 18% Upside Cathay General To Buy Back $75M In Stock